Literature DB >> 33186461

Che-1/AATF-induced transcriptionally active chromatin promotes cell proliferation in multiple myeloma.

Tiziana Bruno1, Francesca De Nicola1, Giacomo Corleone1, Valeria Catena1, Frauke Goeman1, Matteo Pallocca1, Cristina Sorino1, Gianluca Bossi2, Bruno Amadio1, Giovanni Cigliana3, Maria Rosaria Ricciardi4, Maria Teresa Petrucci5, Enrico Pierluigi Spugnini1, Alfonso Baldi6, Mario Cioce2, Giancarlo Cortese1, Elisabetta Mattei7, Roberta Merola3, Umberto Gianelli8, Luca Baldini8, Francesco Pisani9, Svitlana Gumenyuk9, Andrea Mengarelli9, Katja Höpker10, Thomas Benzing10,11,12, Bruno Vincenzi13, Aristide Floridi1, Claudio Passananti14, Giovanni Blandino2, Simona Iezzi1, Maurizio Fanciulli1.   

Abstract

Multiple myeloma (MM) is a hematologic malignancy produced by a clonal expansion of plasma cells and characterized by abnormal production and secretion of monoclonal antibodies. This pathology exhibits an enormous heterogeneity resulting not only from genetic alterations but also from several epigenetic dysregulations. Here we provide evidence that Che-1/AATF (Che-1), an interactor of RNA polymerase II, promotes MM proliferation by affecting chromatin structure and sustaining global gene expression. We found that Che-1 depletion leads to a reduction of "active chromatin" by inducing a global decrease of histone acetylation. In this context, Che-1 directly interacts with histones and displaces histone deacetylase class I members from them. Strikingly, transgenic mice expressing human Che-1 in plasma cells develop MM with clinical features resembling those observed in the human disease. Finally, Che-1 downregulation decreases BRD4 chromatin accumulation to further sensitize MM cells to bromodomain and external domain inhibitors. These findings identify Che-1 as a promising target for MM therapy, alone or in combination with bromodomain and external domain inhibitors.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33186461      PMCID: PMC7686885          DOI: 10.1182/bloodadvances.2020002566

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  58 in total

1.  BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Authors:  Jake E Delmore; Ghayas C Issa; Madeleine E Lemieux; Peter B Rahl; Junwei Shi; Hannah M Jacobs; Efstathios Kastritis; Timothy Gilpatrick; Ronald M Paranal; Jun Qi; Marta Chesi; Anna C Schinzel; Michael R McKeown; Timothy P Heffernan; Christopher R Vakoc; P Leif Bergsagel; Irene M Ghobrial; Paul G Richardson; Richard A Young; William C Hahn; Kenneth C Anderson; Andrew L Kung; James E Bradner; Constantine S Mitsiades
Journal:  Cell       Date:  2011-09-01       Impact factor: 41.582

2.  c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells.

Authors:  Zuqin Nie; Gangqing Hu; Gang Wei; Kairong Cui; Arito Yamane; Wolfgang Resch; Ruoning Wang; Douglas R Green; Lino Tessarollo; Rafael Casellas; Keji Zhao; David Levens
Journal:  Cell       Date:  2012-09-28       Impact factor: 41.582

3.  AATF suppresses apoptosis, promotes proliferation and is critical for Kras-driven lung cancer.

Authors:  Daniela Welcker; Manaswita Jain; Safiya Khurshid; Mladen Jokić; Martin Höhne; Anna Schmitt; Peter Frommolt; Carien M Niessen; Judith Spiro; Thorsten Persigehl; Maike Wittersheim; Reinhard Büttner; Maurizio Fanciulli; Bernhard Schermer; Hans Christian Reinhardt; Thomas Benzing; Katja Höpker
Journal:  Oncogene       Date:  2018-01-11       Impact factor: 9.867

4.  Selective inhibition of tumor oncogenes by disruption of super-enhancers.

Authors:  Jakob Lovén; Heather A Hoke; Charles Y Lin; Ashley Lau; David A Orlando; Christopher R Vakoc; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2013-04-11       Impact factor: 41.582

Review 5.  Novel approaches to treatment of double-refractory multiple myeloma.

Authors:  Hans C Lee; Jatin J Shah; Robert Z Orlowski
Journal:  Am Soc Clin Oncol Educ Book       Date:  2013

Review 6.  Epigenetic modulators, modifiers and mediators in cancer aetiology and progression.

Authors:  Andrew P Feinberg; Michael A Koldobskiy; Anita Göndör
Journal:  Nat Rev Genet       Date:  2016-03-14       Impact factor: 53.242

Review 7.  Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs.

Authors:  Gerard L Brien; Daria G Valerio; Scott A Armstrong
Journal:  Cancer Cell       Date:  2016-04-11       Impact factor: 31.743

8.  Che-1 sustains hypoxic response of colorectal cancer cells by affecting Hif-1α stabilization.

Authors:  Tiziana Bruno; Mariacristina Valerio; Luca Casadei; Francesca De Nicola; Frauke Goeman; Matteo Pallocca; Valeria Catena; Simona Iezzi; Cristina Sorino; Agata Desantis; Cesare Manetti; Giovanni Blandino; Aristide Floridi; Maurizio Fanciulli
Journal:  J Exp Clin Cancer Res       Date:  2017-02-18

9.  MYC dysregulation in the progression of multiple myeloma.

Authors:  Kristine Misund; Niamh Keane; Caleb K Stein; Yan W Asmann; Grady Day; Seth Welsh; Scott A Van Wier; Daniel L Riggs; Greg Ahmann; Marta Chesi; David S Viswanatha; Shaji K Kumar; Angela Dispenzieri; Veronica Gonzalez-Calle; Robert A Kyle; Michael O'Dwyer; S Vincent Rajkumar; K Martin Kortüm; J Jonathan Keats; Rafael Fonseca; A Keith Stewart; W Michael Kuehl; Esteban Braggio; P Leif Bergsagel
Journal:  Leukemia       Date:  2019-08-22       Impact factor: 11.528

Review 10.  Discovering Che-1/AATF: a new attractive target for cancer therapy.

Authors:  Simona Iezzi; Maurizio Fanciulli
Journal:  Front Genet       Date:  2015-04-10       Impact factor: 4.599

View more
  5 in total

1.  AATF is Overexpressed in Human Bladder Cancer and Regulates Chemo-Sensitivity Through Survivin.

Authors:  Shutao Tan; Lin Fu; Qianze Dong
Journal:  Onco Targets Ther       Date:  2021-12-29       Impact factor: 4.147

2.  AATF is Overexpressed in Human Head and Neck Squamous Cell Carcinoma and Regulates STAT3/Survivin Signaling.

Authors:  Lin Fu; Quanxiu Jin; Qianze Dong; Qingchang Li
Journal:  Onco Targets Ther       Date:  2021-11-09       Impact factor: 4.147

3.  Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B.

Authors:  Martina Musella; Andrea Guarracino; Nicoletta Manduca; Claudia Galassi; Eliana Ruggiero; Alessia Potenza; Ester Maccafeo; Gwenola Manic; Luca Mattiello; Sara Soliman Abdel Rehim; Michele Signore; Marco Pietrosanto; Manuela Helmer-Citterich; Matteo Pallocca; Maurizio Fanciulli; Tiziana Bruno; Francesca De Nicola; Giacomo Corleone; Anna Di Benedetto; Cristiana Ercolani; Edoardo Pescarmona; Laura Pizzuti; Francesco Guidi; Francesca Sperati; Sara Vitale; Daniele Macchia; Massimo Spada; Giovanna Schiavoni; Fabrizio Mattei; Adele De Ninno; Luca Businaro; Valeria Lucarini; Laura Bracci; Eleonora Aricò; Giovanna Ziccheddu; Francesco Facchiano; Stefania Rossi; Massimo Sanchez; Alessandra Boe; Mauro Biffoni; Ruggero De Maria; Ilio Vitale; Antonella Sistigu
Journal:  Nat Immunol       Date:  2022-08-24       Impact factor: 31.250

Review 4.  Targeting Reactive Oxygen Species Metabolism to Induce Myeloma Cell Death.

Authors:  Mélody Caillot; Hassan Dakik; Frédéric Mazurier; Brigitte Sola
Journal:  Cancers (Basel)       Date:  2021-05-17       Impact factor: 6.639

5.  CK2-mediated phosphorylation of Che-1/AATF is required for its pro-proliferative activity.

Authors:  Valeria Catena; Tiziana Bruno; Simona Iezzi; Silvia Matteoni; Annalisa Salis; Cristina Sorino; Gianluca Damonte; Maurizio Fanciulli
Journal:  J Exp Clin Cancer Res       Date:  2021-07-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.